10
Participants
Start Date
February 1, 2021
Primary Completion Date
May 15, 2024
Study Completion Date
May 15, 2024
nomacopan (rVA576)
The study population will consist of paediatric patients who have undergone allogeneic or autologous HSCT and develop HSCT-TMA within a year of HSCT
Children's Hospitall of Philadelphia, Philadelphia
Duke University Medical Center, Children's Health Center, Durham
Uniwersytecki Szpital Kliniczny im. Jana Mikulicza Radeckiego we Wroclawiu, Wroclaw
Children's Hospital Los Angeles, Los Angeles
Stanford Children's Hospital, Palo Alto
The Royal Marsden NHS Foundation Trust, London
St. Georges University Hospital, London
Great Ormond Street Hospital (GOSH), London
Royal Manchester Children's Hospital, Manchester
Lead Sponsor
AKARI Therapeutics
INDUSTRY